Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| uniQure N.V.QURE · Entity 4162 | Chief Medical Officer | June 30, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
uniQure N.V.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 148,235 |
Ending reported balance
After 2026-06-30 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-06-30 · Exercise / conversion · Acquired 10,000 · Balance 178,235 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Row 2 · 2026-06-30 · Sale · Disposed 10,000 · Balance 168,235 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.19 to $46.97. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. Row 3 · 2026-06-30 · Sale · Disposed 20,000 · Balance 148,235 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.24 to $46.80. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.59 · Expires 2034-03-01 | Direct | 50,500 |
Reported balance
After 2026-06-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-30 · Exercise / conversion · Disposed 10,000 · Balance 50,500 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F4: The Stock Option was granted on March 1, 2024 and vested 25% on the first anniversary of the date of grant, and vests 6.25% quarterly thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.19 to $46.97. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.24 to $46.80. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
F4: The Stock Option was granted on March 1, 2024 and vested 25% on the first anniversary of the date of grant, and vests 6.25% quarterly thereafter until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 2, 2026 20:59 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0000904454-26-000394 · edgar.xml · derivative · entry 4 Abi-Saab Walid · CIK 0001985973 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,500 Underlying: Ordinary Shares · 10,000 shares Expires 2034-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F4 · derivative.exercise_date: The Stock Option was granted on March 1, 2024 and vested 25% on the first anniversary of the date of grant, and vests 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:59 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 20,000 | $46.40 | $928,000.00 |
DisclosureSEC source: 0000904454-26-000394 · edgar.xml · nonDerivative · entry 3 Abi-Saab Walid · CIK 0001985973 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,235 F1 · kind: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.24 to $46.80. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:59 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 10,000 | $46.46 | $464,600.00 |
DisclosureSEC source: 0000904454-26-000394 · edgar.xml · nonDerivative · entry 2 Abi-Saab Walid · CIK 0001985973 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,235 F1 · kind: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.19 to $46.97. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:59 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionOrdinary Shares | 10,000 | $5.59 | $55,900.00 |
DisclosureSEC source: 0000904454-26-000394 · edgar.xml · nonDerivative · entry 1 Abi-Saab Walid · CIK 0001985973 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 21:06 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,434 | $46.86 | $67,197.24 |
DisclosureSEC source: 0000904454-26-000387 · edgar.xml · nonDerivative · entry 1 Abi-Saab Walid · CIK 0001985973 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,235 F1 · kind: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F1 · shares: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.69 to $46.96. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 08, 2026 Filed May 12, 2026 20:54 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0000904454-26-000260 · edgar.xml · derivative · entry 4 Abi-Saab Walid · CIK 0001985973 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,500 Underlying: Ordinary Shares · 25,000 shares Expires 2034-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · derivative.exercise_date: The Stock Option was granted on March 1, 2024 and vested 25% on the first anniversary of the date of grant, and vests 6.25% quarterly thereafter until fully vested. Read SEC document |
| May 08, 2026 Filed May 12, 2026 20:54 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 20,000 | $25.00 | $500,000.00 |
DisclosureSEC source: 0000904454-26-000260 · edgar.xml · nonDerivative · entry 3 Abi-Saab Walid · CIK 0001985973 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 169,669 F1 · kind: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| May 08, 2026 Filed May 12, 2026 20:54 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 25,000 | $25.10 | $627,500.00 |
DisclosureSEC source: 0000904454-26-000260 · edgar.xml · nonDerivative · entry 2 Abi-Saab Walid · CIK 0001985973 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,669 F1 · kind: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.29. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 08, 2026 Filed May 12, 2026 20:54 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionOrdinary Shares | 25,000 | $5.59 | $139,750.00 |
DisclosureSEC source: 0000904454-26-000260 · edgar.xml · nonDerivative · entry 1 Abi-Saab Walid · CIK 0001985973 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 214,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:59 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 67,200 | $0.00 Strike: $9.04 | $0.00 |
DisclosureSEC source: 0000904454-26-000161 · edgar.xml · derivative · entry 3 Abi-Saab Walid · CIK 0001985973 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,200 Underlying: Ordinary Shares · 67,200 shares Expires 2036-03-04 F4 · derivative.exercise_date: The Stock Option vests 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:59 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 808 | $9.06 | $7,320.48 |
DisclosureSEC source: 0000904454-26-000161 · edgar.xml · nonDerivative · entry 2 Abi-Saab Walid · CIK 0001985973 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,669 F2 · kind: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F2 · shares: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.22. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:59 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 41,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-26-000161 · edgar.xml · nonDerivative · entry 1 Abi-Saab Walid · CIK 0001985973 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,477 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:25 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,660 | $9.95 | $16,517.00 |
DisclosureSEC source: 0000904454-26-000148 · edgar.xml · nonDerivative · entry 1 Abi-Saab Walid · CIK 0001985973 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,777 F1 · kind: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F1 · shares: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.67 to $10.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 20:49 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,466 | $13.92 | $20,406.72 |
DisclosureSEC source: 0000904454-25-000350 · edgar.xml · nonDerivative · entry 1 Abi-Saab Walid · CIK 0001985973 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,437 F1 · kind: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F1 · shares: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.90 to $14.05. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 22:28 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,350 | $10.29 | $13,891.50 |
DisclosureSEC source: 0000904454-25-000180 · edgar.xml · nonDerivative · entry 2 Abi-Saab Walid · CIK 0001985973 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,903 F2 · kind: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F2 · shares: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.25 to $10.35. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:28 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 66,000 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0000904454-25-000180 · edgar.xml · derivative · entry 3 Abi-Saab Walid · CIK 0001985973 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,000 Underlying: Ordinary Shares · 66,000 shares Expires 2035-03-03 F4 · derivative.exercise_date: The Stock Option vests 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:28 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 38,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-25-000180 · edgar.xml · nonDerivative · entry 1 Abi-Saab Walid · CIK 0001985973 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,253 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:21 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,447 | $4.36 | $6,308.92 |
DisclosureSEC source: 0000904454-24-000409 · edgar.xml · nonDerivative · entry 1 Abi-Saab Walid · CIK 0001985973 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,253 F1 · kind: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F1 · shares: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.35 to $4.36. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:10 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 85,500 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0000904454-24-000199 · edgar.xml · derivative · entry 2 Abi-Saab Walid · CIK 0001985973 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,500 Underlying: Ordinary Shares · 85,500 shares Expires 2034-03-01 F2 · derivative.exercise_date: The Stock Option vests 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:10 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 49,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-24-000199 · edgar.xml · nonDerivative · entry 1 Abi-Saab Walid · CIK 0001985973 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,700 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.